Non-Hallucinogenic Psychedelic Compound

Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic

Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines

Delix's Non-Hallucinogen Completes Safe Administration To First Clinical Trial Cohort

Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines

Delix's Non-Hallucinogen Completes Safe Administration To First Clinical Trial Cohort

BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue

Psychedelics For Treating Depression: New Research Finds Key In BDNF Receptor

BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue

Psychedelics For Treating Depression: New Research Finds Key In BDNF Receptor

MA, FL And OH Psychedelics Scientists And Educators' Latest Research And Views

Another Win For Non-Hallucinogens: Meet Psilera's Candidates Poised For Clinical Stage Milestone

Non-Hallucinogenic Psychedelic Compound Recent News

Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic

The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc.

BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs

BetterLife Pharma (OTCQB: BETRF), a non-hallucinogenic psychedelics biotech company, has contracted Bloom Burton Securities Inc. for strategic advisory services.

Ceruvia Lifesciences Begins Dosing Volunteers In Research On Non Hallucinogenic LSD Compound

Clinical-stage psychedelics biopharma company Ceruvia Lifesciences has dosed the first participant in its Phase 1 trial on NYPRG-101, aka BOL-148, an LSD non-hallucinogenic analog with a clinical and experimental administration history that dates back to the 1950s.

Psychedelics & Role Of Memory In Healing Process, New Trial Led By Univ. Of Wisconsin

The University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances (TCRPS) was created to foster education and research on the field of medical applications of psychedelics, and one of them is specifically studying if remembering the psychedelic-induced hallucinations is a fundamental part of these substances' therapeutic effects.

Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives

In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings.

This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects

Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.